Systemic DNase I

About Xenetic Biosciences

Xenetic Biosciences is a lean, platform-focused biotech advancing its systemic DNase I candidate as an adjunctive therapy to re-sensitize tumors to existing treatments. The company's strategy targets a novel mechanism of action—degrading neutrophil extracellular traps (NETs)—to address chemotherapy and immunotherapy resistance in solid tumors. With its lead program poised for clinical entry and a leadership team featuring deep oncology and business development expertise, Xenetic aims to create value through platform validation and strategic partnerships.

About Xenetic Biosciences

Xenetic Biosciences is a lean, platform-focused biotech advancing its systemic DNase I candidate as an adjunctive therapy to re-sensitize tumors to existing treatments. The company's strategy targets a novel mechanism of action—degrading neutrophil extracellular traps (NETs)—to address chemotherapy and immunotherapy resistance in solid tumors. With its lead program poised for clinical entry and a leadership team featuring deep oncology and business development expertise, Xenetic aims to create value through platform validation and strategic partnerships.

Therapeutic Areas